Rinath Jeselsohn, Director for ER+ Breast Cancer Translational and Discovery Research, Breast Oncology Center at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“I am thrilled to share that our manuscript was just published in Genome Medicine.
By combining high-complexity clonal lineage tracing with genomic and transcriptomic analyses, we were able to follow how ER-positive breast cancers evolve under the selective pressure of CDK4/6 inhibitors.
One of the most exciting findings is that both ESR1 mutation status and the choice of CDK4/6 inhibitor shape distinct evolutionary trajectories, resulting in different patterns of clonal selection and adaptive cell states during acquired resistance. These findings provide new insights into the biology of resistance and may help inform more effective therapeutic strategies for patients with ER-positive breast cancer.
A special congratulations and thank you to Cristina Guarducci, the first author of this study, and to all our collaborators at DFCI and The Broad Institute. It has been a privilege to work with you on this exciting research.”
Title: ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance
Authors:
Read the Full Article.
You can also read:
Can Routine Pathology Slides Improve Breast Cancer Risk Assessment?
